The search for atrial fibrillation and its impact on public health

Lam Anna, Goulouti Eleni, Roten Laurent

Department of Cardiology, Inselspital, Bern University Hospital and University of Bern, Switzerland

Summary
Atrial fibrillation may be clearly symptomatic and is easily amenable to state-of-the-art treatment, most importantly oral anticoagulation therapy for the prevention of thromboembolism. However, atrial fibrillation may also go unnoticed for long periods in many patients. This silent or subclinical atrial fibrillation is nevertheless associated with thromboembolic risk just like clinically evident atrial fibrillation. Early detection of atrial fibrillation in patients at increased thromboembolic risk and consequent oral anticoagulation therapy may have a significant impact on public health. This review focuses on screening recommendations for atrial fibrillation and on the impact of silent atrial fibrillation in various clinical scenarios.

Key words: atrial fibrillation, screening, ischaemic stroke, silent brain lesion, atrial high rate episodes, atrial cardiomyopathy.

Introduction
Atrial fibrillation is an endemic disease affecting 3% of the adult population with a prevalence of about 1% at the age of 60 years, increasing to >15% at the age of 85 years [1]. The number of patients affected by atrial fibrillation is expected to double by the year 2050 because of the aging population [2]. Atrial fibrillation is the leading cause of ischaemic stroke and is highly prevalent in stroke patients, with prevalence increasing steeply with age [3]. Atrial fibrillation is not only associated with an increased risk of stroke, but also increases the risk of heart failure and all-cause mortality [4]. Atrial fibrillation has also been linked to silent brain lesions, as well as cognitive impairment and dementia [5, 6]. Once atrial fibrillation is diagnosed, oral anticoagulation therapy is initiated in most patients to prevent thromboembolic events, thereby significantly lowering morbidity and mortality [7].

However, atrial fibrillation is often clinically silent and therefore not diagnosed or only discovered late, at the time of an event such as an ischaemic stroke [8, 9]. Silent atrial fibrillation is a challenging problem for public health: early identification and treatment of affected subjects, maybe even subjects at risk of atrial fibrillation, might further lower morbidity and mortality.

Screening for atrial fibrillation in the general population
Back in 2012, atrial fibrillation guidelines recommended only opportunistic screening for atrial fibrillation in patients aged ≥65 years by pulse palpation followed by an electrocardiogram in the case of an irregular pulse. With this simple community screening approach, atrial fibrillation can be identified in about 1.4% of subjects not previously known to have atrial fibrillation [10]. And according to the guidelines, oral anticoagulation therapy should be considered in all of these patients, as thromboembolic risk is elevated in patients aged ≥65 years [7]. Since 2012, recommendations for atrial fibrillation screening have evolved significantly as a result of various studies, which will be presented hereafter (table 1).

More advanced, stepwise community screening was tested in a Swedish study: screening of a population aged 75–76 years with at least one additional stroke risk factor by means of 12-lead ECG, and, if negative, by repeat handheld ECG identified new atrial fibrillation in an additional 1% and 7.4% of subjects, respectively [11]. The same group thereafter expanded the stepwise screening programme to include 7173 subjects aged 75–76 years, i-
Atrial fibrillation in ischaemic stroke patients

As discussed above, the prevalence of atrial fibrillation in the general population rises steeply with age. This is also true among ischaemic stroke patients, with the difference that prevalence rates of atrial fibrillation are about fourfold higher in each age group compared with the general population [8]. Many patients with known atrial fibrillation presenting with ischaemic stroke have received either no anticoagulation or sub-therapeutic anticoagulation [8, 21]. These patients also have worse outcome from ischaemic stroke than patients with atrial fibrillation and therapeutic anticoagulation presenting with ischaemic stroke [21].

Again, primary emphasis from a public health standpoint should be to treat patients known to have atrial fibrillation according to guidelines. Monitoring of ischaemic stroke patients for the presence of atrial fibrillation is nevertheless mandatory: an admission ECG will yield about 7.7% of new atrial fibrillation cases, in-hospital monitoring an additional 5.1% of cases and ambulatory Holter monitoring 10.7% [9]. Extending monitoring to 30 days with event-triggered recording following an ischaemic stroke has yielded 16.1% of new atrial fibrillation cases [22]. With the implantation of a loop recorder, the rate of new atrial fibrillation cases increases up to 30% after 3 years [23]. The overall atrial fibrillation detection rate after ischaemic stroke including admission ECG, in hospital and ambulatory monitoring may add up to well over 20% of cases [9]. As a result, screening for atrial fibrillation after an ischaemic stroke by short-term ECG recording followed by continuous ECG monitoring up to 72 hours is a class I indication in the current atrial fibrillation guidelines (table 1). Additionally, prolonged noninvasive monitoring or implantation of a loop recorder after an ischaemic stroke is a class IIa indication.

Importantly, screening of atrial fibrillation in ischaemic stroke patients should not be restricted to cryptogenic stroke patients or patients presenting with a most probable origin for embolic stroke according to the TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification, because competing causes of ischaemic stroke are frequently present [24].

Studies are currently in the recruiting phase that randomise ischaemic stroke patients without an atrial fibrillation diagnosis to oral anticoagulation therapy versus aspirin (Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source [NAVIGATE ESUS;ClinicalTrials.gov identifier: NCT02313909] and Dabigatran Exetilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source [RE-SPECT ESUS; NCT02239120]). If these studies prove superiority of oral anticoagulation therapy, screening for atrial fibrillation after an ischaemic stroke may be less important in the future.

Atrial fibrillation in silent stroke patients

The prevalence of silent brain lesions is age dependent and generally reported in the range of 10 to 20% in most studies, with an annual incidence of 2 to 4% [25, 26]. Silent brain lesions are not harmless: patients with silent brain lesions have an increased risk of dementia and a steeper decline in cognitive function than those without such lesions [27]. The presence of silent brain lesions also increases the risk of new silent brain lesions three-fold, and the risk of symptomatic ischaemic stroke two-fold [26, 28].

On the other hand, brain imaging studies comparing patients with and without atrial fibrillation but no history of ischaemic stroke have reported an important association of atrial fibrillation with silent brain lesions (odds ratio 2.62, 95% confidence interval 1.81–3.80) [5]. The prevalence of silent brain lesions on computed tomography and magnetic resonance imaging among patients with atrial fibrillation in these studies has been reported to be 22 and 40%, respectively [5]. Whether such silent brain lesions in atrial fibrillation patients are cardioembolic in origin or whether their coexistence with atrial fibrillation is simply a reflection of shared risk factors remains to be proven.

Atrial fibrillation is probably the most important cause of cardioembolic, typically large and clinically relevant, ischaemic strokes. Nevertheless, cardioembolic strokes can certainly also occlude smaller vessels, depending on the diameter of the embolus. Although causes other than atrial fibrillation may be responsible for a bigger proportion of smaller ischaemic strokes than of larger strokes, atrial fibrillation may still be an important and underestimated player.
To date, no study has rigorously investigated the presence of atrial fibrillation in patients with silent brain lesions. As a consequence, prolonged rhythm monitoring to search for atrial fibrillation is nowadays routinely performed in ischaemic stroke patients, but not in patients with silent brain lesions.

**Atrial high-rate episodes a cardiac implantable electronic devices**

The number of patients with cardiac implantable electronic devices including an atrial lead is steadily growing. These devices permit continuous monitoring for atrial high-rate episodes exceeding a programmable or device-specific duration. If this function is enabled, a notification will appear upon device interrogation if an episode fulfilling programmed criteria occurred (fig. 1). Such notifications may also be transmitted daily by remote monitoring if this feature is enabled, allowing for continuous, almost real-time arrhythmia screening. Several studies have reported an association of atrial high-rate episodes with clinically diagnosed atrial fibrillation, as well as increased risk of ischaemic stroke and even mortality [29–31]. Interestingly, atrial high-rate episodes have also been reported to be an independent predictor for silent brain lesions [32].

Different cut-offs have been used, but generally a duration exceeding 5 to 6 minutes is accepted as a criterion for relevant atrial high-rate episodes (by definition, rates have to be >180 bpm). Current guidelines have also been adapted accordingly (table 1) [7]. In the event of atrial high-rate episodes, the presence of atrial fibrillation should be verified on a corresponding electrogram from the device (fig. 2) or on a standard ECG or rhythm strip, and anticoagulation should be initiated according to guidelines. Verification of atrial fibrillation is important, because atrial high-rate episodes may also correspond to noise or far field electrograms, etc. On an individual basis, patients with atrial high-rate episodes at high stroke risk may also be anticoagulated without electrogram or ECG verification of atrial fibrillation. However, the benefit of anticoagulation in patients with atrial high-rate episodes is currently less well established than in patients with atrial fibrillation. Several studies currently underway are testing the benefit of oral anticoagulation therapy in patients with atrial high rate episodes (e.g. Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation [ARTESIA; NCT01938248] and Non vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes [NOAH; NCT02618577]). However, much has still to be learned about the causal relationship between atrial high-rate episodes and thromboembolism: many thromboembolic events in the studies mentioned above were not temporally associated with atrial high-rate episodes [33, 34]. Finally, it also has to be emphasised that patients with cardiac implantable electronic devices represent a very select patient population with advanced cardiac disease, and these findings cannot be generalised to other populations.

**Atrial fibrillation as a causative or surrogate factor for thromboembolic risk**

As discussed above, atrial high-rate episodes and atrial fibrillation are associated with ischaemic stroke, but the temporal relationship is intriguingly loose. This raises the question of whether atrial fibrillation is in fact the cause or rather a surrogate factor of increased thromboembolic risk. Interestingly, both the CHA2DS2-VASc score as well as the CHADS2 score can predict ischaemic stroke events in populations without known atrial fibrillation with similar accuracy to that in populations with atrial fibrillation, although the event rate is somewhat lower [35–37]. On the other hand, frequent premature atrial contractions are also an independent predictor of ischaemic stroke, even when...
subjects are censored in the event of an atrial fibrillation diagnosis [38]. Subjects with a CHA2DS2-VASc score ≥2 and frequent premature atrial contractions are reported to have an ischemic stroke risk of 2.4%, very similar to historical populations with atrial fibrillation [38]. Subjects with higher CHA2DS2-VASc scores certainly have more advanced vascular disease, which may also increase thromboembolic risk independently of atrial fibrillation. However, except for the rare cases of primary electrical disease, patients with atrial fibrillation have some kind of atrial cardiomyopathy leading to atrial fibrillation [39]. According to Virchow’s triad, haemodynamic changes, endothelial injury and hypercoagulability all contribute to thrombosis. The increased risk of thromboembolism attributed to atrial arrhythmias may partly be explained by associated haemodynamic changes. But the occurrence of premature atrial contractions, atrial high-rate episodes and eventually atrial fibrillation may also be interpreted as a surrogate of more advanced atrial fibrosis and inflammation, i.e., atrial cardiomyopathy leading to endothelial injury and hypercoagulability, and resultant increased thromboembolic risk. Most probably, atrial fibrillation is both a causative and a surrogate factor of increased thromboembolic risk (fig. 3). Maybe expanding the CHA2DS2-VASc score to also include premature atrial contractions or a diagnosis of atrial fibrillation would serve well as a more general approach for thromboembolic risk calculation in the general population. To our knowledge, no studies are currently planned to randomise patients with a high CHA2DS2-VASc score but without atrial fibrillation to anticoagulation therapy versus no therapy, except the studies of patients after ischemic stroke discussed above. But with the advent of the novel oral anticoagulants, the time for such studies is probably not so far away anymore.

Disclosure statement
This work was supported by grants from the Swiss National Science Foundation and the Swiss Heart Foundation. The authors have no potential conflict of interest relevant to this article.

References


14 De Vos CB, Weis B, Crijns HJ, Cierici EC, Palsmans A, Habets J, et al. Atrial tissue Doppler imaging for prediction of new-onset atrial fibrilla-


18 Shibasaki K, Kimura K, Fujii S, Saki K, Ijichi V. Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitaliza-

19 Wallmann D, Tilller D, Kucher N, Fuhrer J, Arnold M, Delacretaz E. Frequent atrial premature contractions as a surrogate marker for parox-


21 Hylek EM, Go AS, Chang Y, Jensvold HG, Henriot LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortali-


23 Santha T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al.; CRYSTAL AF Investigators. Cryptogenic stroke and under-


25 Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain in-


29 Goelte TV, Hellkamp AS, Zimmerman M, Sweeney MO, You R, Marin-


34 Daoud EG, Goelte TV, Wyse DG, Ezekowitz MD, Hilkert C, Koehler J, et al.; TRENDs Investigators. Temporal relationship of arterial tach-


36 Wells CC, WHOoley MA, Na B, Ganz P, Schiller NB, Turakhia MP. The CHADS2 score predicts ischemic stroke in the absence of atrial fibrilla-

37 Ntaios G, Lip GY, Makaritsis K, Papavasiliou V, Vennou A, Korobo-


39 Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, et al. EHRA/HRS/APHRS/SOLAFEC expert consensus on atrial cardiomy-